X4 PHARMACEUTICALS, INC Earnings Per Share (Basic)
X4 PHARMACEUTICALS, INC (XFOR) reported Earnings Per Share (Basic) of -$0.13 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC earnings per share, basic for the quarter ending 2026-06-30 was -$0.13.
- X4 PHARMACEUTICALS, INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.16, a 500.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC earnings per share, basic for the quarter ending 2025-09-30 was -$0.69.
- X4 PHARMACEUTICALS, INC earnings per share, basic for the quarter ending 2025-06-30 was -$3.47, a 125.53% decline year-over-year.
- X4 PHARMACEUTICALS, INC earnings per share, basic for fiscal 2025 was -$1.87.
- X4 PHARMACEUTICALS, INC earnings per share, basic for fiscal 2024 was -$5.59.
- X4 PHARMACEUTICALS, INC earnings per share, basic for fiscal 2023 was -$17.07.
- X4 PHARMACEUTICALS, INC earnings per share, basic for fiscal 2022 was -$1.52.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.13 10-Q · filed 2026-08-06 | -$0.29 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | -$0.16 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | -$1.87 10-K · filed 2026-03-17 | |||||||
| 2025-09-30 | -$0.69 10-Q · filed 2025-11-05 | -$2.87 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | -$3.47 10-Q · filed 2026-08-06 | -$3.59 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | $0.04 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | -$5.59 10-K · filed 2026-03-17 | -$0.19 10-K · filed 2025-03-26 | ||||||
| 2024-09-30 | -$5.48 10-Q · filed 2025-11-05 | -$0.18 10-Q · filed 2024-11-13 | $0.35 10-Q · filed 2025-11-05 | $0.01 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $13.59 10-Q · filed 2025-08-08 | $0.45 10-Q · filed 2024-08-08 | $5.85 10-Q · filed 2025-08-08 | $0.20 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | -$7.77 10-Q · filed 2025-05-01 | -$0.26 10-Q · filed 2024-05-07 | $0.29 derived: net income ÷ weighted average shares · filed 2026-03-17 | $0.77 derived: net income ÷ weighted average shares · filed 2026-03-17 | $4.44 derived: net income ÷ weighted average shares · filed 2026-03-17 | |||
| 2023-12-31 | $0.04 derived: net income ÷ weighted average shares · filed 2026-03-17 | $0.15 derived: net income ÷ weighted average shares · filed 2026-03-17 | $1.88 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$17.07 10-K · filed 2026-03-17 | -$0.57 10-K · filed 2024-03-21 | |||
| 2023-09-30 | -$0.01 10-Q · filed 2024-11-13 | -$0.32 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$0.48 10-Q · filed 2024-11-13 | -$0.73 derived: net income ÷ weighted average shares · filed 2025-03-26 | ||||
| 2023-06-30 | -$0.33 10-Q · filed 2024-08-08 | -$0.51 10-Q · filed 2024-08-08 | -$0.79 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$1.05 derived: net income ÷ weighted average shares · filed 2025-03-26 | ||||
| 2023-03-31 | -$0.16 10-Q · filed 2024-05-07 | -$0.43 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$0.68 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$1.05 derived: net income ÷ weighted average shares · filed 2025-03-26 | ||||
| 2022-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$0.55 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$0.99 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$1.52 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | -$0.26 10-Q · filed 2023-11-09 | -$0.73 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.32 10-Q · filed 2023-11-09 | -$2.28 derived: net income ÷ weighted average shares · filed 2024-03-21 | ||||
| 2022-06-30 | -$0.60 10-Q · filed 2023-08-10 | -$1.31 10-Q · filed 2023-08-10 | -$2.49 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$3.25 derived: net income ÷ weighted average shares · filed 2024-03-21 | ||||
| 2022-03-31 | -$0.72 10-Q · filed 2023-05-04 | -$1.92 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$2.70 derived: net income ÷ weighted average shares · filed 2024-03-21 | |||||
| 2021-12-31 | -$1.24 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$2.02 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$3.99 10-K · filed 2024-03-21 | |||||
| 2021-09-30 | -$0.76 10-Q · filed 2022-11-03 | -$2.71 10-Q · filed 2022-11-03 | ||||||
| 2020-12-31 | -$3.09 10-K · filed 2023-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |